IDEAYA Biosciences Inc (NASDAQ:IDYA), a United States-based oncology-focused biotechnology company, has dosed its first patient in the phase one combination study of IDE196 and binimetinib, an MEK inhibitor, intended to treat metastatic uveal melanoma (MUM), it was reported on Thursday.
The company is assessing the clinical combination of IDE196 and binimetinib, which is being provided by Pfizer based on a clinical trial collaboration and supply contract.
The company expects interim data from the MEK combination study in late 2021 to early 2022, when the firm will assess a potential registrational path for MUM and a potential collaboration.
Anixa Biosciences transfers breast cancer vaccine IND from Cleveland Clinic
RedHill Biopharma reports positive opaganib data in venetoclax-resistant CLL
Genmab completes tender offer for Merus and opens subsequent offering period
NanOlogy launches drug development program for diffuse intrinsic pontine glioma treatment
Privo Technologies doses first patient in first-in-human clinical trial of PRV131
Senhwa Biosciences signs clinical supply agreement with BeOne Medicines
D3 Bio completes USD108m Series B financing round
Champions Oncology expands bioanalytical services with new technology and leadership
Poolbeg Pharma trial to feature in major CRS research programme